Showing 211-220 of 4743 results for "".
FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Conversations in Acne, Part 3
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-3/19877/What do we know about the anti-inflammatory effects of antibiotics? How can we reduce risks for creating resistance or affecting the gut microbiome? Host Neal Bhatia, MD leads a conversation on these topics and more with Hilary Baldwin, MD and James Q. Del Rosso, DO.DermWireTV: Impact of COVID-19 on Dermatology
https://practicaldermatology.com/topics/practice-management/dermwiretv-impact-of-covid-19-on-dermatology/19878/As COVID-19 infections surge across the US, a vaccine has been approved. What's it mean for dermatology patients? And how is the pandemic impacting dermatology practices? Updates from the International Psoriasis Council; Mark Nestor, MD; Amy Taub, MD; Terrence Keaney, MD; and Melissa Kanchanapoomi LJejunal Trichobezoar in a 3-year-old Boy; Practice Path MD Pro Tip: Architects
https://practicaldermatology.com/youngmd-connect/resident-resource-center/jejunal-trichobezoar-in-a-3-year-old-boy-practice-path-md-pro-tip-architects/20697/Hailey-Hailey Disease and Pemphigus Foliaceus; Preview: Practice PATH MD; Call for Case Reports
https://practicaldermatology.com/youngmd-connect/resident-resource-center/hailey-hailey-disease-and-pemphigus-foliaceus-preview-practice-path-md-call-for-case-reports/20752/Live in Las Vegas: Get Ready for DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/live-in-las-vegas-get-ready-for-derm2021/19968/The DERM2021 NP/PA CME Conference offers dermatology physician assistants and nurse practitioners an opportunity to stay up to date on the latest products, drugs, and treatments in dermatology to improve care for patients. Joe Gorelick, MSN, FNP-BC, DEF President, says this year’s conference is goinIntergenerational Dermatology: Two Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-two-generations-of-dermatologists-reflect-on-the-field-2/23937/With Heidi A. Waldorf, MD, and Donald S. Waldorf, MDDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PBespoke for Bros: A Different Approach for Male Patients
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bespoke-for-bros-a-different-approach-for-male-patients-/19561/Physical features aside, there may be important differences in how male patients think about and approach cosmetic concerns. According to Heidi Waldorf, MD, while women tend to seek a youthful appearance, men often want to appear as though they have not aged—and stopping the aging clock requires a f